Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “AstraZeneca”
Sponsor: AstraZeneca
Chronic Kidney Disease
United States
Sponsor: AstraZeneca
Breast Neoplasms · Breast Cancer · Neoplasm Metastasis
Germany
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
United States, Australia, Austria, Belgium, Brazil +16 more
Sponsor: AstraZeneca
Advanced Solid Malignancies
United States, Australia, Germany, South Korea, Spain +2 more
- Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.Active Not Recruiting
Sponsor: AstraZeneca
Eosinophilic Granulomatous Vasculitis
United States, Belgium, Canada, France, Germany +4 more
Sponsor: AstraZeneca
Clostridioides Difficile Infection
United States, Australia, Canada, Denmark, France +9 more
Sponsor: AstraZeneca
Neurofibromatosis Type 1
Egypt
Sponsor: AstraZeneca
Breast Cancer · Biliary Tract Carcinoma · Ovarian Cancer · Endometrial Cancer
United States, Australia, Belgium, Canada, China +10 more
Sponsor: Memorial Sloan Kettering Cancer Center
Metastatic Non-small Cell Lung Cancer
United States
Sponsor: AstraZeneca
Non-Small-Cell Lung
China
- An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma PatientsActive Not Recruiting
Sponsor: AstraZeneca
Asthma
China
Sponsor: AstraZeneca
Lupus Erythematosus, Systemic
United States, Australia, Canada, United Kingdom
Sponsor: AstraZeneca
Chronic Lymphocytic Leukaemia · Small Lymphocytic Lymphoma · Mantle-cell Lymphoma · Large B-cell Lymphoma
United States, Australia, China, Czechia, Denmark +8 more
- A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNot Yet Recruiting
Sponsor: AstraZeneca
Heart Failure With Preserved Ejection Fraction (HFpEF) · Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
United States, Argentina, Australia, Austria, Brazil +20 more
Sponsor: AstraZeneca
Rare Diseases · Generalized Myasthenia Gravis (gMG)
Russia
Sponsor: Fred Hutchinson Cancer Center
Lung Carcinoma
United States
- A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLCNot Yet Recruiting
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung
- A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast CancerActive Not Recruiting
Sponsor: AstraZeneca
Breast Cancer
United States, Australia, Belgium, Canada, Denmark +13 more
- Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With DurvalumabEnrolling By Invitation
Sponsor: AstraZeneca
Cancer
United States, Argentina, Australia, Belgium, Brazil +26 more
- OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR AmyloidosisRecruiting
Sponsor: AstraZeneca
ATTR Amyloidosis
United States, Canada, China, Denmark, Germany +6 more
Sponsor: AstraZeneca
Primary Membranous Nephropathy
United States, Belgium, France, Germany, Italy +3 more
Sponsor: AstraZeneca
Pan-tumor(NSCLC, GYN Cancers, BTC and UC)
China
- RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid CancersActive Not Recruiting
Sponsor: Memorial Sloan Kettering Cancer Center
Thyroid Cancer
United States
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
United States, Argentina, Australia, Bulgaria, Canada +19 more
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerActive Not Recruiting
Sponsor: AstraZeneca
Breast Neoplasms · Breast Cancer · HER2-positive Early Breast Cancer
United States, Brazil, Bulgaria, Canada, China +13 more